Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Regeneron

Regeneron Pharmaceuticals Stock: Analyst Estimates & Ratings

Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Barchart

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

MarketBeat

Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and more.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

Barchart

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Intellia's Single-Dose Gene Editing Treatment for ATTR Amyloidosis Gets FDA Fast-Track Approval Boost

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA)

Benzinga

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is expected to report its fiscal third-quarter earnings this month, and analysts project a single-digit profit plunge.

Barchart

Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500?

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Barchart

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.

Barchart

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Barchart

Regeneron To Defend Against DOJ Complaint On Drug Pricing

Regeneron faces DOJ legal challenge over drug-price manipulation allegations, vows to defend itself. Case could impact pharmaceutical industry and drug pri...

Top News

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

US Appeals Court Revives Regeneron Antitrust Lawsuit Against Novartis

U.S. appeals court revives Regeneron's antitrust lawsuit against Novartis, highlighting alleged anticompetitive behavior.

StockNews.com

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

Top News

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron Pharmaceuticals surpasses expectations with strong fourth-quarter revenue, boosting investor confidence in the company's performance.

Top News

Eylea Sales Soar, Regeneron Breaks Records with Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 Billion!

Regeneron's Q4 sales of Eylea skyrocketed to a staggering Eylea Sales Soar, Regeneron Breaks Records with Top News.34 Billion!.34 billion in the U.S., sending shockwaves through the pharmaceutical industry. Incredible suc...

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

StockNews.com

Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Corcept Therapeutics (CORT), and Incyte (INCY). Read more.

StockNews.com

3 Biotechs with Massive Growth Potential

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

StockNews.com

3 Biotech Gainers to Consider

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

Tribune News Service

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

Evening Standard

What was the longest-running Covid infection and how were they cured?

A British man tested positive for Covid for more than two years and survived - but many more have Long Covid

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

The Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.